ADCY7 Protein — Adenylate Cyclase 7

ADCY7 Protein — Adenylate Cyclase 7

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">ADCY7 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>ADCY7 (Adenylyl Cyclase 7)</td></tr>
<tr><td><strong>Gene</strong></td><td>[ADCY7](https://www.ncbi.nlm.nih.gov/gene/115)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P51828](https://www.uniprot.org/uniprot/P51828)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Adenylate cyclase family (Class III)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~130 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Plasma membrane, intracellular vesicles</td></tr>
<tr><td><strong>Expression</strong></td><td>Brain (high in cerebellum, hippocampus), immune cells</td></tr>
<tr><td><strong>Chromosome Location</strong></td><td>16q12.2</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

ADCY7 Protein — Adenylate Cyclase 7

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">ADCY7 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>ADCY7 (Adenylyl Cyclase 7)</td></tr>
<tr><td><strong>Gene</strong></td><td>[ADCY7](https://www.ncbi.nlm.nih.gov/gene/115)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P51828](https://www.uniprot.org/uniprot/P51828)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Adenylate cyclase family (Class III)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~130 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Plasma membrane, intracellular vesicles</td></tr>
<tr><td><strong>Expression</strong></td><td>Brain (high in cerebellum, hippocampus), immune cells</td></tr>
<tr><td><strong>Chromosome Location</strong></td><td>16q12.2</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

ADCY7 (Adenylate Cyclase 7) is a membrane-bound enzyme that catalyzes the conversion of ATP to cyclic AMP (cAMP), a crucial second messenger in cellular signaling.[@conti2000] ADCY7 is one of nine mammalian adenylate cyclase isoforms (ADCY1-9), each with distinct regulatory properties, expression patterns, and cellular functions [1].[@sunahara2000] ADCY7 is partic[@rankin2005]ularly abundant in the brain and immune system, where it plays essential roles in synaptic plasticity, memory formation, immune cell activation, and inflammatory responses.

Adenylate cyclases serve as critical effectors for G protein-coupled receptors (GPCRs), transducing extracellular signals into intracellular cAMP production. The cAMP/PKA/CREB signaling pathway is fundamental to learning and memory processes, and its dysregulation has been implicated in numerous neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD) [2]. ADCY7, as a brain-enriched isoform, is centrally involved in these processes and represents a potential therapeutic target.

The cAMP signaling cascade affects multiple downstream effectors, including protein kinase A (PKA), cAMP-responsive element-binding protein (CREB), Epac (exchange protein directly activated by cAMP), and cyclic nucleotide-gated (CNG) channels. Through these effectors, ADCY7-derived cAMP influences synaptic plasticity, gene transcription, ion channel function, and cellular metabolism—all processes critical to neuronal survival and function [3].

Structure

ADCY7 is a large transmembrane protein with a complex architecture enabling its enzymatic function and regulatory capacity:

Overall Organization

ADCY7 consists of two main regions:

Transmembrane Domains

• Two transmembrane modules: Each contains six helical segments
• Membrane localization: Anchors the enzyme to the plasma membrane
• Signal input: Couples to G proteins in the membrane

Catalytic Domains

The cytoplasmic catalytic domains form the functional core [4]:

C1a Domain (N-terminal catalytic):

• Contains the ATP binding site
• Binds forskolin
• Interacts with Gαs and Gβγ subunits
• Contains the catalytic core motif (DGIEE)

• Forms dimer with C1a
• Contains additional regulatory sites
• Binds forskolin and Gαs

Regulatory Features

ADCY7 has unique regulatory properties:

• Forskolin sensitivity: Activated by forskolin (plant diterpene)
• G protein regulation:
• Activated by Gαs subunits
• Inhibited by Gαi/o subunits
• Modulated by Gβγ complexes
• Calcium regulation: Inhibited by calmodulin (CaM) in some isoforms
• PKA phosphorylation: Can be regulated by PKA-mediated phosphorylation

Structural Model

The architecture enables:

• Dimer formation: Two catalytic domains form a functional dimer
• Substrate access: ATP access from cytoplasmic side
• cAMP release: cAMP exported to cytoplasm
• Allosteric regulation: Multiple regulatory inputs

Normal Function

cAMP Production in Neurons

ADCY7 produces cAMP in response to multiple upstream signals [5]:

Gαs-Coupled Receptor Activation

• Dopamine D1 receptors (D1R, D5R): Major pathway in striatum and cortex
• β-adrenergic receptors (β1, β2, β3): Noradrenergic signaling
• Serotonin receptors (5-HT4, 5-HT6, 5-HT7): Serotonergic modulation
• Adenosine A2 receptors (A2A, A2B): Adenosinergic signaling
• Prostaglandin receptors (EP2, EP4): Prostaglandin signaling

Direct Activation

• Forskolin: Bypasses receptor signaling for direct AC activation
• Forskolin-analogues: Research tools for studying cAMP production

Modulation by Gβγ

• Bidirectional regulation: Can either stimulate or inhibit depending on isoform and context
• Cell-type specificity: Different effects in different neuronal populations

Synaptic Plasticity

cAMP generated by ADCY7 is essential for multiple forms of synaptic plasticity [6]:

Long-Term Potentiation (LTP)

• PKA-dependent LTP: cAMP/PKA pathway critical for late-phase LTP
• CREB activation: PKA phosphorylates CREB, driving gene expression
• Synaptic strengthening: AMPA receptor trafficking and function

Long-Term Depression (LTD)

• cAMP contribution: Required for certain forms of LTD
• Protein synthesis: cAMP-dependent protein synthesis
• Endocytosis: AMPA receptor internalization

Memory Consolidation

Synaptic Tagging and Capture

• Tag formation: Synaptic tags marked by cAMP/PKA
• Capture: Proteins synthesized and delivered to tagged synapses
• Consolidation: Long-term synaptic change

Neuronal Excitability

ADCY7-derived cAMP modulates neuronal excitability through [8]:

Ion Channel Regulation

• PKA phosphorylation: Modulates voltage-gated calcium channels
• HCN channels: Hyperpolarization-activated cyclic nucleotide-gated channels
• Sodium channels: Nav1.x channel modulation

Transporter Activity

• Neurotransmitter reuptake: Modulates neurotransmitter transporters
• Ion pumps: Na+/K+ ATPase regulation

Second Messenger Crosstalk

• Ca²⁺ signaling: Interaction with calcium signaling pathways
• MAPK pathway: cAMP can activate MAPK signaling
• PKC interaction: Cross-talk with protein kinase C pathways

Immune Function

ADCY7 is highly expressed in immune cells [9]:

B Cell Activation

• cAMP signaling: Modulates antibody production
• Proliferation: Affects B cell expansion
• Differentiation: Influences plasma cell formation

T Cell Function

• T cell activation: Regulates T cell receptor signaling
• Cytokine production: Modulates IL-2 and other cytokine production
• Treg function: Affects regulatory T cell activity

Inflammation Modulation

• Inflammatory responses: Regulates cytokine release
• Neuroinflammation: Relevant to neuroinflammatory conditions
• Autoimmunity: Implications for autoimmune diseases

Expression Pattern

ADCY7 has a distinctive expression pattern:

Brain Regions

• Cerebellum: High expression, particularly in Purkinje cells
• Hippocampus: CA1, CA3 regions, dentate gyrus
• Cortex: Layer 5 pyramidal neurons
• Striatum: Medium spiny neurons
• Hypothalamus: Various nuclei
• Brainstem: Limited expression

Immune Cells

• B cells: High expression
• T cells: Moderate expression
• Macrophages: Variable expression
• Dendritic cells: Present

Other Tissues

• Heart: Low expression
• Lung: Present
• Kidney: Low expression

Role in Neurodegeneration

Alzheimer's Disease

ADCY7 is implicated in multiple aspects of Alzheimer's disease pathogenesis [10]:

Amyloid-β Pathophysiology

Aβ reduces ADCY7 activity, impairing cAMP signaling:

• Direct interaction: Aβ oligomers can directly inhibit adenylate cyclase
• Receptor coupling: Aβ impairs Gαs-coupled receptor signaling
• cAMP reduction: Decreased cAMP production in affected neurons
• Synaptic failure: Impaired cAMP/PKA signaling contributes to synaptic dysfunction

Synaptic Dysfunction

cAMP signaling is critical for synaptic function:

• LTP impairment: Reduced cAMP/PKA signaling impairs LTP
• Memory consolidation: Disrupted CREB-mediated gene expression
• AMPA trafficking: Impaired AMPA receptor trafficking
• Dendritic spines: Effects on spine morphology and number

Tau Pathology

cAMP signaling interacts with tau phosphorylation pathways [11]:

• Kinase regulation: cAMP/PKA can regulate tau kinases
• Phosphatase regulation: Modulates tau phosphatases
• Aggregation: cAMP may affect tau aggregation
• Clearance: Autophagy regulation affects tau clearance

Therapeutic Implications

Targeting cAMP signaling in AD:

• Phosphodiesterase inhibitors: Enhance cAMP by preventing degradation (e.g., rolipram, PDE4 inhibitors)
• cAMP analogs: Pharmacological approaches to bypass defective adenylate cyclase
• ADCY7 modulators: Direct activators of ADCY7
• CREB activators: Enhance CREB-mediated transcription

Clinical Evidence

• PDE inhibitors: Mixed results from clinical trials
• cAMP elevation: Improvement in some cognitive measures
• Research directions: Novel approaches in development

Parkinson's Disease

ADCY7 is centrally involved in dopaminergic signaling [12]:

D1 Receptor Signaling

D1 receptor-mediated cAMP production:

• Striatal function: Direct pathway activation
• Motor control: Movement initiation and execution
• Reward learning: Reinforcement and habit formation

D2 Receptor Inhibition

Gαi-mediated inhibition affects D2 signaling:

• Indirect pathway: D2 striatal signaling
• Motor inhibition: Pathway to hypokinesia
• L-DOPA response: Adenylate cyclase activity influences levodopa efficacy

Neuroprotection

cAMP-activated pathways can protect dopaminergic neurons:

• Survival pathways: cAMP/PKA activates pro-survival signaling
• Mitochondrial function: cAMP affects mitochondrial dynamics
• Oxidative stress: cAMP can enhance antioxidant responses
• Neuroinflammation: Anti-inflammatory effects of cAMP

L-DOPA-Induced Dyskinesia

cAMP dysregulation contributes to LID:

• Dyskinesia mechanisms: Abnormal cAMP signaling
• Therapeutic targets: PDE inhibitors under investigation
• Combination therapy: Potential for cAMP modulation

Other Neurodegenerative Conditions

Huntington's Disease

• cAMP signaling: Reduced in HD models
• Therapeutic potential: PDE inhibitors showing promise

Multiple Sclerosis

• Oligodendrocyte function: cAMP affects myelination
• Neuroinflammation: Modulates inflammatory responses

Amyotrophic Lateral Sclerosis (ALS)

• Motor neuron survival: cAMP-mediated neuroprotection
• Glial activation: Modulates neuroinflammation

Signaling Pathways

cAMP/PKA/CREB Pathway

Gαs-coupled receptor → ADCY7 → cAMP → PKA → CREB → Gene transcription
↓
Multiple cellular effects

Effectors

Protein Kinase A (PKA)

• Substrate phosphorylation: Multiple neuronal substrates
• Synaptic proteins: AMPA, NMDA receptor modulation
• Transcription factors: CREB activation

CREB

• Gene transcription: Drives expression of plasticity-related genes
• Synaptic proteins: BDNF, c-Fos, other plasticity molecules
• Neuronal survival: Pro-survival gene expression

Epac (Exchange Protein directly Activated by cAMP)

• Rap activation: Small GTPase signaling
• Synaptic plasticity: Independent of PKA
• neurite outgrowth: Promotes neuronal development

Cross-Talk

Calcium Signaling

• cAMP/Ca²⁺ interaction: Bidirectional modulation
• CaM sensitivity: CaM can regulate adenylate cyclases
• Activity-dependent signaling: Integration of signals

MAPK Pathway

• cAMP-activated MAPK: Through Epac/Rap or PKA
• Synaptic plasticity: MAPK contributes to LTP
• Cell survival: MAPK-mediated pro-survival signaling

Phosphodiesterases

• cAMP breakdown: PDEs regulate cAMP levels
• Therapeutic targets: PDE inhibitors enhance cAMP signaling
• Specificity: Different PDE isoforms in different cells

Therapeutic Targeting

Phosphodiesterase Inhibitors

| Drug | Target | Status | Potential |
|------|--------|--------|-----------|
| Rolipram | PDE4 | Research | Memory enhancement |
| Sildenafil | PDE5 | Approved | Cognitive effects under study |
| Ibudilast | PDE4, others | Clinical trials | Neuroprotection |
| Aplindore | PDE4 | Research | Parkinson's disease |

Direct Adenylate Cyclase Activators

• Forskolin: Research tool, not clinically used
• Analogues: Synthetic derivatives under development
• GPCR agonists: Enhance physiological activation

cAMP Analogs

• 8-Br-cAMP: Cell-permeable cAMP analog
• Db-cAMP: Dibutyryl cAMP
• 8-CPT-2'-O-Me-cAMP: Epac-selective cAMP analog

CREB Modulators

• CREB activators: Enhance transcription
• BDNF mimetics: Downstream effectors

Challenges

• Specificity: Achieving isoform specificity
• Brain penetration: Blood-brain barrier challenges
• Side effects: cAMP systemically affects many organs
• Timing: Optimal intervention in disease course

Animal Models

Knockout Models

• ADCY7 KO mice: Viable, with immunological deficits
• Conditional KO: Tissue-specific deletion
• Phenotype studies: Reveal isoform-specific functions

Transgenic Models

• Overexpression: Enhanced cAMP signaling
• Dominant negative: Reduced function
• Humanized: Expressing human ADCY7

Disease Models

• AD models: APP/PS1 with cAMP modulation
• PD models: MPTP, α-synuclein with cAMP studies
• Learning models: Pavlovian conditioning

Genetic Variation

Polymorphisms

• Coding variants: Affect enzyme function
• Promoter variants: Influence expression levels
• Disease associations: Potential links to neuropsychiatric disorders

Clinical Implications

• Drug response: Variability in PDE inhibitor response
• Disease risk: Potential modifier of neurodegeneration

Biomarkers

Peripheral Markers

• Immune cell cAMP: Reflects systemic signaling
• PDE activity: Peripheral PDE levels
• Genetic markers: SNP associations

CNS Markers

• Imaging: Limited options for cAMP imaging
• CSF markers: Under investigation
• Functional measures: Cognitive testing

Research Directions

Novel Therapeutics

• Brain-penetrant PDE inhibitors: Improved CNS penetration
• Allosteric modulators: Target specific isoforms
• Combination approaches: Multi-target strategies

Biomarker Development

• Response prediction: Genetic and expression markers
• Disease monitoring: Therapeutic efficacy markers

Mechanism Studies

• ADCY7-specific functions: Differentiate from other isoforms
• Cell-type specificity: Understand neuronal vs. glial roles
• Developmental aspects: Role in brain development

See Also

• [ADCY7 Gene](/genes/adcy7)
• [cAMP Signaling](/mechanisms/camp-signaling)
• [Synaptic Plasticity](/mechanisms/long-term-potentiation)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [CREB Signaling](/mechanisms/creb-signaling)
• [Phosphodiesterases](/proteins/pde-family)

External Links

• [UniProt P51828](https://www.uniprot.org/uniprot/P51828)
• [NCBI Gene ADCY7](https://www.ncbi.nlm.nih.gov/gene/115)
• [GeneCards ADCY7](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADCY7)
• [IUPHAR Database](https://www.guidetopharmacology.org/record/GPCR/1619)
• [Human Protein Atlas](https://www.proteinatlas.org/ENSG00000121201-ADCY7)

References